Host effects contributing to cancer therapy resistance
Ofrat Beyar‐Katz(Rambam Health Care Campus), Yuval Shaked(Technion – Israel Institute of Technology)
Cited by 44
Related Papers
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
|Blood Advances|2021|170
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study
|Transplantation and Cellular Therapy|2021|164
Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells
|Cancer Research|2018|103
Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia
|Leukemia|2019|69
Novel Approaches to Acute Myeloid Leukemia Immunotherapy
|Clinical Cancer Research|2018|63